A phase 3 randomized clinical trial using a once‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesity

AIM: To evaluate the efficacy, safety and tolerability of a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in patients with hypothalamic obesity (HO). MATERIALS AND METHODS: A two‐arm, randomized, multicentre, double‐blind, placebo‐controlled trial was conducted in 10‐ to 25‐year‐olds with hypo...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Christian L., Perez, Francisco A., Whitlock, Kathryn B., Elfers, Clinton, Yanovski, Jack A., Shoemaker, Ashley H., Abuzzahab, M. Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821019/
https://www.ncbi.nlm.nih.gov/pubmed/33026160
http://dx.doi.org/10.1111/dom.14224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821019/
https://www.ncbi.nlm.nih.gov/pubmed/33026160
http://dx.doi.org/10.1111/dom.14224

Ejemplares similares